AQR Capital Management LLC Sells 77,371 Shares of Zimmer Biomet Holdings, Inc. $ZBH

AQR Capital Management LLC lowered its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 18.3% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 345,309 shares of the medical equipment provider's stock after selling 77,371 shares during the quarter. AQR Capital Management LLC owned approximately 0.17% of Zimmer Biomet worth $38,761,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Garde Capital Inc. bought a new position in shares of Zimmer Biomet in the first quarter worth about $29,000. Washington Trust Advisors Inc. bought a new position in Zimmer Biomet in the 1st quarter valued at approximately $30,000. Columbia River Financial Group LLC bought a new position in Zimmer Biomet in the 1st quarter valued at approximately $30,000. Menard Financial Group LLC bought a new position in Zimmer Biomet in the 4th quarter valued at approximately $30,000. Finally, Accent Capital Management LLC bought a new position in Zimmer Biomet in the 1st quarter valued at approximately $35,000. Institutional investors own 88.89% of the company's stock.

Wall Street Analysts Forecast Growth

ZBH has been the subject of a number of research reports. UBS Group raised their price objective on shares of Zimmer Biomet from $91.00 to $96.00 and gave the company a "sell" rating in a report on Friday, August 8th. Raymond James Financial raised their price objective on shares of Zimmer Biomet from $104.00 to $113.00 and gave the company an "outperform" rating in a report on Friday, August 8th. Royal Bank Of Canada raised their price objective on shares of Zimmer Biomet from $112.00 to $115.00 and gave the company an "outperform" rating in a report on Friday, August 8th. Evercore ISI dropped their price objective on shares of Zimmer Biomet from $102.00 to $96.00 and set an "in-line" rating for the company in a report on Tuesday, July 8th. Finally, Roth Capital reiterated a "buy" rating on shares of Zimmer Biomet in a report on Thursday, August 7th. Nine analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Zimmer Biomet has a consensus rating of "Hold" and a consensus price target of $111.00.

Insider Activity at Zimmer Biomet

In other news, insider Sang Yi sold 1,000 shares of Zimmer Biomet stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total transaction of $95,000.00. Following the sale, the insider directly owned 20,424 shares in the company, valued at $1,940,280. The trade was a 4.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.70% of the stock is owned by insiders.

Zimmer Biomet Trading Down 0.8%

Shares of NYSE:ZBH traded down $0.87 during mid-day trading on Tuesday, hitting $103.84. The company had a trading volume of 1,282,597 shares, compared to its average volume of 1,220,309. The firm has a fifty day moving average price of $98.89 and a 200 day moving average price of $99.61. The company has a market capitalization of $20.57 billion, a PE ratio of 25.27, a price-to-earnings-growth ratio of 2.06 and a beta of 0.68. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96. Zimmer Biomet Holdings, Inc. has a one year low of $89.22 and a one year high of $114.72.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The business had revenue of $2.08 billion during the quarter, compared to the consensus estimate of $2.06 billion. During the same quarter last year, the firm posted $2.01 EPS. Zimmer Biomet's revenue was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be given a $0.24 dividend. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $0.96 annualized dividend and a yield of 0.9%. Zimmer Biomet's payout ratio is currently 23.36%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.